Unique ID issued by UMIN | UMIN000010123 |
---|---|
Receipt number | R000011142 |
Scientific Title | Prospective study of efficacy and safety of preoperative transcatheter arterial chemolipiodolization with miriplatin for hepatocellular carcinoma.(Phase I study) |
Date of disclosure of the study information | 2013/02/26 |
Last modified on | 2014/01/30 14:50:53 |
Prospective study of efficacy and safety of preoperative transcatheter arterial chemolipiodolization with miriplatin for hepatocellular carcinoma.(Phase I study)
Phase I trial of preoperative Chemolipiodolization with miriplatin for hepatocellular carcinoma.
Prospective study of efficacy and safety of preoperative transcatheter arterial chemolipiodolization with miriplatin for hepatocellular carcinoma.(Phase I study)
Phase I trial of preoperative Chemolipiodolization with miriplatin for hepatocellular carcinoma.
Japan |
Hepatocellular carcinoma
Hepato-biliary-pancreatic surgery |
Malignancy
NO
To assess the safety of preoperative transcatheter arterial chemolipiodolization with miriplatin for hepatocellular carcinoma.
Safety
Exploratory
Explanatory
Phase I
Safety
Operative duration, Intraoperative blood loss, Hospital stay, Complications
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
Medicine |
Transcatheter arterial chemolipiodolization with miriplatin
20 | years-old | <= |
Not applicable |
Male and Female
1) Age over 20 years old.
2) Written informed consent
3) The tumor number <= 3 nodules in the liver. The maximum tumor diameter without limit.
4) Adequate organ function for 2 weeks before transcatheter arterial chemolipiodolization with miriplatin.
1) Patients who have medical history of hypersensitivity of platinum-containing drug, iodine-containing drug and gelatine.
2) Patients with serious complications(Severe thyroid disease, Severe heart disease and the like)
3) Patients with active double cancer.
4) Patients with bile duct invasion.
5) Pregnant and lactating females; males and females of childbearing age unless using effective contraception.
6) Patients without remarkable findings of A-V shunt and/or A-P shunt.
7) Tumor thrombosis in main portal vein or vena cava.
8) Patients who are concluded to be inappropriate to participate in this study by their physicians.
6
1st name | |
Middle name | |
Last name | Keiichi Kubota |
Dokkyo Medical University
Second department of surgery
Kitakobayashi 880, Mibu, Shimotsuga, Tochigi
0282-86-1111
xx@dokkyomed.ac.jp
1st name | |
Middle name | |
Last name | Masato Kato |
Dokkyo Medical University
Second department of surgery
Kitakobayashi 880, Mibu, Shimotsuga, Tochigi
0282-86-1111
katomasa@dokkyomed.ac.jp
Second department of surgery, Dokkyo Medical University
none
Self funding
NO
2013 | Year | 02 | Month | 26 | Day |
Unpublished
Completed
2012 | Year | 10 | Month | 01 | Day |
2013 | Year | 02 | Month | 25 | Day |
2013 | Year | 10 | Month | 24 | Day |
2013 | Year | 10 | Month | 24 | Day |
2013 | Year | 10 | Month | 24 | Day |
2013 | Year | 02 | Month | 26 | Day |
2014 | Year | 01 | Month | 30 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000011142